Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
more notes:
analyst: have you applied to NYSE as well?
Dowling: no; we are evaluating that in near term as well. I am not pessimistic about NASD so we haven't started
Scott from Roth Cap partners: Are retailers waiting on FDA?
Dowling: no they are not waiting. Things are changing quickly re Gottlieb and we think there will be three lanes to be established 1 Pharma, 2 OTC CBD products, 3 THC cannabis products. CBD will need to be hemp from a raw material hemp food/fiber seed strain - "many CBD providers today are from MJ/THC strains. I don't think FDA will allow these."
more live notes...
NASDAQ - nothing new. We've given them everything, continue to respond, and will keep everyone updated
Analyst: what is go to market strategy on retail?
Dowling: all different based on food, drug, broad retailers - first working closely with FDMC marketers on type of products that will be made, regions and store they want.
Analyst: what are the retailers telling us? Do they know about GRAS and do they ask about it and care?
Dowling: its part of the education; may retailers already understand GRAS standards and deal with it for many products; we expect it to be part of the eventual FDA regulations
Dowling: safety continues to be critical; CVSI positioned well for this
Analyst: how is capacity to serve large orders now?
Dowling: raw materials good, always evaluated; product partners are preparing and scaling; we are "ready today" by scaling all of our manuafacturing, packaging and fulfillment to handle demand we expect
Some notes as we go...
Mentioning how state interference disrupted Q4 and will persist through Q1..
Mentioned Dr. Duffy McKay - positive leader for FDA relations...
Gummies going well and now thinking of additional form factors...
"We believe distribution is on the verge of broadening to food, drug, and more traditional distribution channels."
mentioning awards...
At 14.2 Q4 and $48.2 for FY is good for investors and a profitable growing business; but I would expect short term annoying share price drop and impatient traders selling, and other usual suspects predicting the end of this growing, profitable $50mil business that just became legal...
listening to call now...
Can someone explain the rev benefit of smokable? Its all still within the medical mj area - will this drive increases?
Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. A telephone replay will be available approximately two hours after the call concludes and will be available through Tuesday, March 19, 2019, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13688167.
1:30 p.m. Pacific Standard Time (4:30 p.m. Eastern Standard Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's web site at https://ir.cvsciences.com/news-events and at http://public.viavid.com/index.php?id=133332. The webcast will be archived for approximately 30 days.
I smell $5... (or maybe $4.68...) Last half hour could be a doozy. Finally some mildly positive green volume back first time since late Jan...
Space Lady - please revise my store count to 2792. I just visited each one last week and counted them myself. (Lost my job, my family left me, and my dog is threatening to leave, but it was totally worth it for the gummies.)
Thanks erpy - so sideways since we were cut off. Looks like it is up significantly today - people anticipating a solution? That email from CEO was helpful.
How is Canada price today for VFF?
I second this... he loves screwing up the CVSI board. CBD hater on a quest to be right and spam CBD boards...
Anyone know when earnings are coming out? This board is quiet as is the stock. Low volume fade. They seem promising, but need more good news
NowWhat - do you like the reversal now? esp of this holds over $13 USD by end of the day
In same article was some more validation that GRAS study is only good for one company, not all. Gives a good sense about how rigorous CVSI is:
"The company is one of a handful that is investing seriously in clinical trials to support its products on both sides of the Rx / non-Rx divide. CV has also taken a step that Tomc wishes more companies would follow: thorough toxicological studies.
“The only way you can argue that you’re not in violation of the Food Drug & Cosmetic Act is to do the toxicology and show that your formulation is safe,” said Tomc in an interview. CV has done extensive analysis on its formulas—which are derived from a well-characterized strain of food-grade hemp aerial plant parts.
“We have total confidence in our lab, which is fully GMP compliant, and audited by Eurofins (an international network of food, supplement, and agricultural safety testing labs). We have an adverse events reporting system in place, and we established No Observed Adverse Effects Levels (NOAEL) status for our products, per criteria in the Food, Drug & Cosmetic Act. This is the first formal toxicological work done on a hemp extract since 1981.”
Since hemp oil formulations vary greatly—each company is developing its own formulas, using different extraction methods, and including (or excluding) different cannabinoids—it is essential that each brand prove the safety of its own products.
I read the article twice at $50 mil before it changed. Thanks Balding for the note re need to release. I was wondering about how they would handle that. Will be interesting to see.
It seems possible to have 16 mil rev last Q which would get them to 50
I hope Tomc knows the number is higher and he was just speaking in round numbers.
If Tomc is accurate and rev is 50mil even That would put Q4 at 16mil rev and QoQ growth at 18%. YoY growth of 250% That would be a good quarter given the ‘choppiness’ and that it wasn’t legal until Dec 21.
I wonder if this will reverse out of 11s and back to 12s by close of the day. The volume is so light on this crappy exchange this seems easily manipulated down. I have this problem with many of my US mj and cbd stocks. This company is best in class yet SP has to fight with blindfold on on OTC Pink... Lets get the earnings out there to change this narrative...
75 million shares locked up with officers until July 25 at least.
Artie V:
Re GRAS - in my email exchange with IR last week, they confirmed that CVSI believes their GRAS study will apply to them only and not to all companies. That makes sense and reaffirms my confidence in management. I wouldn't want them to spend $$ on altruistic industry benefits. I trust them over Artie V's many, many, many, many emails to the contrary.
entire sector red today
That is a rough shaking - not sure where bounce will come
I would expect a pullback after this run up from $5 (USD) and I will be buying. On April 1, 18 mil shares get added to the 131 million. If share price in USD climbs to $8 by March 31 then and then drops 10%-12% that day, I'd be ok with that short term dilution for the free cash flow and balance sheet gain. PLus some of that dilution effect will be baked in SP by then. The more I research OGI the more impressed I am.
I see the link at top of this page - thanks
I think that is a great indicator for financial management. Was that in the PR yesterday about the province agreement? Or do you have a link?
What PR are you worried about?
I'm hoping the GWPH gap up on earnings today will help focus on CBD and those who hope to be in CBD pharma/sciences side...
This regulatory and banking trend is our friend...
https://www.cnbc.com/2019/02/26/congress-asked-the-fed-chief-about-marijuana-banking.html
Thanks Emerald - any further response from FDA to congress re the Feb 22 deadline?
I think steps like this yesterday https://www.cnbc.com/2019/02/26/congress-asked-the-fed-chief-about-marijuana-banking.html
and earlier in Feb
https://www.forbes.com/sites/tomangell/2019/02/06/the-first-marijuana-hearing-of-the-new-congress-has-been-scheduled/#6a4a9c411287
Are the keys to NASD and NYSE being able to list MJ and CBD companies. Its trending in the right direction.
Great - do you (or anyone on this board) know if there is a 1:1 correlation between the Canadian volume and the OTC Pink Sheet volume?
Cutting Canadian and any lingering Aphria ties before buy out. Why would statement mention acting CEO resident of Florida and CFO from Illinois... these statements are more likely to say "was head marketing for so and so" or "has an MBA and CPA from here and there"
If there are any feet on the street that can verify that Liberty Dispensaries are full of clients (? anyone?) then this feels like a house cleaning for takeover.
2x Volume on US OTC; how does that compare to Canadian volume today? Nice move on just 330K shares - lets see what happens with 1 - 2 mil traded on a green day...
I emailed IR re GRAS and they were very quick and pleasant. Key line in bold. We'll see if that holds.
>>>>>>>>>>>>
Sent: Tuesday, February 19, 2019 3:17 PM
One other question on the status of self-affirmed GRAS please: is it CV Sciences contention that Self-Affirmed GRAS will be lead to FDA approval of only the CVSI proprietary CBD because of the CVSI process?; or would the FDA approval of our Self-affirmed GRAS mean that CBD would then be approved as GRAS for anyone to use the status? There is a lot of confusion out there about the use and value of the research we did and whether it will uniquely benefit CVSI, or if all companies will gain.
Thanks,
>>>>>>>>>>>>
Answer from IR:
"Generally, a GRAS application comes from the ingredient supplier, not the finished product supplier like CVSI and we aren’t selling to other finished supplement producers. So, I do not believe that GRAS status will apply to any other CBD producer, as has historically been the case. The FDA doesn’t approve research on supplements, yes on the drug development side, but for supplements, the FDA doesn’t approve efficacy, just weighs in on safety."
Balding: what is "the other one" you are comparing here? I don't think (most) people mind an honest side by side comparison of CVSI stats (cost/mg, sales, shipping costs etc) vs competitors with stats like this esp if you can show the sources. I'd like to see what you are saying. I'm not investing 10% of my net worth in CVSI without being honest.
Also, FWIW: I love we are Gras self-certified and think it will provide advantages. But *so far* I don't see them. I hope those advantages are being pressed behind the scenes as we speak.
Happy Presidents Day / Washington's Birthday / Uniform Monday Holiday Act to US; and happy Family Day in Canada. Enjoy the day
Good catch Sleuth - I also sent messages to the reporters with the link to our website for PlusCBD https://pluscbdoil.com/
I am long both CVSI and CWBHF and do think reasonable (ie. non bashing/pumping) discussion of the other top brands/competitors on these boards can be useful.
The story and source of CWBHF hemp is one of the great parts of this brand.
So, FWIW: CVSI hemp was from Dun Agro in Netherlands; the GRAS study was by AIBMR in Seattle who has done hundreds of these for many food additives, supplements; the study was published in Journal of Toxicology. Until FDA gets organized, this does Its all easy to find with the google machine.
Thanks RogJr - really helpful info. That increase in amount dispensed must vary up and down based on week of the month? Great to increase 20% over the last week, but does that have to do with being the first of the month?